Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.
Elina KaprioRoosa PrusilaSusanna TokolaMilla E L KuusistoEsa JantunenHanne KuitunenTaina Turpeenniemi-HujanenOuti KuittinenPublished in: Cancer medicine (2024)
These findings suggest that the use of G-CSF increases the risk of DIP, when used in combination with rituximab-containing regimen.